Bing

SEARCH HISTORY

AstraZeneca plc (LON:AZN)‘s stock had its “outperform” rating reissued by research analysts at BNP Paribas in a research note issued to investors on Monday, MarketBeat reports. They presently have a GBX 5,500 ($85.91) target price on the ...
Ticker Report · 8 hours ago
AstraZeneca plc
Healthcare stocks declined broadly on Wall Street on Thursday morning, with the sector seeing an overall decline of 0.7%. More broadly, the Dow Jones Industrial Average was down 0.5%, the Nasdaq fell 0.4% and the S&P 500 was down 0.5%. Some of the …
Investor Place · 7/30/2015
Healthcare Stocks
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating restated by stock analysts at Deutsche Bank in a research report issued on Friday, Market Beat reports. They currently have a GBX 4,850 ($75.28) price target on the biopharmaceutical …
wkrb13.com · 8/1/2015
More from Bing News
AZN) in a research report released on Friday morning, ARN reports. They currently have a GBX 4,850 ($75.76) target price on the biopharmaceutical company’s stock. AstraZeneca plc (LON:AZN) opened at 4320.00 on Friday. The company’s market ...
sleekmoney.com · 12 hours ago
AstraZeneca plc
AZN) to a buy ratingin a research report report published onFriday, StockTargetPrices.com reports. They currently have $38.00 price target on the biopharmaceutical company’s stock. AstraZeneca plc (NYSE:AZN) opened at 33.79 on Friday. The firm has a ...
Mideast Times · 4 hours ago
AstraZeneca plc
The stock was strong after-hours ... which was being co-developed with AstraZeneca (NYSE:AZN). This was due to suicides in patients on the drug. The Street was expecting that brodalumab would be an important drug that could keep Enbrel's psoriasis and ...
Seeking Alpha · 4 minutes ago
AMGN
CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new ...
Financial Content · 12 hours ago
Isis Pharmaceuticals
We’ll see how this one goes. AstraZeneca stock is still overvalued by about 20%/25%, according to my calculations, but I’d probably bet on it rather than on the shares of Centrica. Why? I prefer Astra’s management team. Moreover, I never buy ...
Motley Fool UK · 7/27/2015
Centrica PLC
AstraZeneca currently carries a Zacks Rank #3 (Hold). Actelion Ltd. ALIOF and Isis Pharmaceuticals, Inc. ISIS are some better-ranked stocks in the health care sector, each carrying a Zacks Rank #1 (Strong Buy).
NASDAQ · 7/31/2015
AstraZeneca plc (AZN - Analyst Report) reported second-quarter 2015 core earnings of $1.21 per American Depositary Share, up 3% (at constant exchange rates or CER) from the year-ago period. Earnings were significantly above the Zacks Consensus …
ZACKS · 7/31/2015
Earnings

AstraZeneca

Company
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, United Kingdom…
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by 2012 prescription drug sales and has operations in over 100 countries.
Data from: Wikipedia